Oldwick, New Jersey-based Provention Bio’s PRV-6527, which was licensed from Johnson & Johnson company Janssen, failed in a mid-stage clinical trial.
Japan’s Takeda Pharmaceutical presented more data from the company’s Phase IIIb head-to-head VARSITY clinical trial of Entyvio compared to AbbVie’s Humira in ulcerative colitis.
RedHill Biopharma reported positive safety and efficacy results from a late-stage clinical trial for the Israeli company’s treatment for Crohn’s disease called RHB-104.
Janssen Pharmaceutical of Johnson & Johnson inked a global collaboration deal with Theravance Biopharma to develop a drug for inflammatory bowel diseases (IBD).
Takeda Pharmaceutical Company Limited and Portal Instruments announced a collaboration to develop and commercialize Portal’s needle-free drug delivery device for potential use with Takeda’s investigational or approved biologic medicines.
J&J subsidiary Janssen inked a collaboration deal to develop Protagonist Therapeutics’ PTG-200 for various gastrointestinal diseases.
Johnson & Johnson said the U.S. Food and Drug Administration approved the company’s blockbuster psoriasis drug Stelara for adults with Crohn’s disease.
With the 2015 record-breaking biopharma merger-and-acquisition period about to come to an end, analysts are tuning their crystal balls to 2016. So far this year—not quite done yet—there has been […]
AstraZeneca enters into agreement with Perrigo for rights to Entocort in the US Divestment further sharpens focus on three main therapy areas Agreement follows ex-US divestment of Entocort in July […]
Johnson & Johnson’s Stelara was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn’s disease, according to data from a late stage […]
